Blue Note Therapeutics develops clinically validated prescription digital therapeutics aimed at reducing anxiety, depression, and other distress related to cancer. The company collaborates with leading cancer centers, community oncology clinics, and patient teams to create solutions that serve all cancer patients, from early-stage through survivorship, in both inpatient and outpatient settings. Blue Note's business model focuses on providing oncology-specific mental health care through digital platforms, partnering with organizations like the National Comprehensive Cancer Network (NCCN) to ensure the highest standards of care. Revenue is generated through the development and distribution of FDA-approved digital devices and applications designed to improve the emotional well-being of cancer patients. The company also offers free wellness apps, such as Attune OTC, to specific communities, including Spanish-speaking patients.

Keywords: digital therapeutics, cancer care, mental health, oncology, anxiety reduction, depression management, prescription apps, patient well-being, FDA-approved, community partnerships.